Oncology Expert Insights

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.

Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.

Dr Pegram discusses the use of oral SERDs in HR-positive metastatic breast cancer and biomarker testing practices for patients with metastatic disease.

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.

Dr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.

Dr Paik discusses the VISION trial of tepotinib in NSCLC harboring MET exon 14 skipping alterations and real-world data from the TOGETHER pooled analysis.

Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed.

Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Drs Merkow and Connell discuss the use of HAI therapy for patients with colorectal cancer.

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

Dr Kyriakopoulos sheds light on the potential synergy between masofaniten and enzalutamide when used in combination for patients with prostate cancer.

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.